BriaCell Therapeutics Prices Public Offering at $3.25 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 42 minutes ago
0mins
Source: NASDAQ.COM
- Public Offering Pricing: BriaCell Therapeutics Corp. has priced its public offering at $3.25 per share for 1.45 million shares, expecting total gross proceeds of approximately $4.7 million, indicating a proactive approach to financing.
- Clear Use of Proceeds: The company intends to utilize the net proceeds for working capital requirements, general corporate purposes, and advancing its business objectives, reflecting a strategic plan for future growth.
- Market Performance Volatility: Over the past year, BCTX's stock has traded between $2.98 and $36.90; despite closing last Friday up 1.68% at $3.64, it fell 12.64% to $3.18 in the overnight market, highlighting the stock's sensitivity to market fluctuations.
- Underwriter's Role: ThinkEquity is acting as the sole placement agent for the offering, underscoring its significant role in the capital markets and potentially influencing investor confidence in the stock.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCTX
About BCTX
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BriaCell Announces Pricing of 1.45 Million Shares at $3.25 Each
- Funding Size: BriaCell Therapeutics Corp. announced the offering of 1,449,300 common shares at $3.25 each, expecting gross proceeds of approximately $4.7 million, which will be used for working capital and advancing corporate objectives, indicating the company's active engagement in capital markets.
- Offering Arrangement: The offering is being managed solely by ThinkEquity and is expected to close on June 2, 2026, reflecting the company's strategic planning in financing aligned with market demand.
- Compliance Assurance: The company is relying on the exemption set forth in Section 602.1 of the TSX Company Manual, ensuring that the transaction complies with relevant regulations, which enhances investor confidence in the company's compliance.
- Future Outlook: BriaCell intends to use the proceeds to advance its cancer immunotherapy development, demonstrating the company's commitment to long-term growth and innovation in the biotechnology sector, which may attract more investor interest in its future potential.
See More
BriaCell Therapeutics Prices Public Offering at $3.25 per Share
- Public Offering Pricing: BriaCell Therapeutics Corp. has priced its public offering at $3.25 per share for 1.45 million shares, expecting total gross proceeds of approximately $4.7 million, indicating a proactive approach to financing.
- Clear Use of Proceeds: The company intends to utilize the net proceeds for working capital requirements, general corporate purposes, and advancing its business objectives, reflecting a strategic plan for future growth.
- Market Performance Volatility: Over the past year, BCTX's stock has traded between $2.98 and $36.90; despite closing last Friday up 1.68% at $3.64, it fell 12.64% to $3.18 in the overnight market, highlighting the stock's sensitivity to market fluctuations.
- Underwriter's Role: ThinkEquity is acting as the sole placement agent for the offering, underscoring its significant role in the capital markets and potentially influencing investor confidence in the stock.
See More
BriaCell's Immunotherapy Study Receives Positive DSMB Recommendation
- Clinical Trial Progress: BriaCell Therapeutics' Bria-ABC study in metastatic breast cancer has received its sixth consecutive positive recommendation from the independent Data Safety Monitoring Board, indicating no safety concerns and allowing the trial to proceed without modifications.
- FDA Fast Track Designation: Conducted under FDA Fast Track designation, the study underscores the significant unmet medical need in metastatic breast cancer, highlighting the strategic importance of the company's development of novel immunotherapies.
- CEO's Positive Remarks: CEO Dr. William V. Williams described this milestone as 'another step forward,' emphasizing BriaCell's commitment to addressing urgent patient needs and advancing its immunotherapy approach.
- Stock Performance Volatility: BCTX shares have traded between $2.98 and $36.90 over the past year, closing at $3.49, down 6.18% from the previous trading day, reflecting market caution regarding the company's future prospects.
See More
BriaCell's Phase 3 Study Receives Sixth Positive DSMB Recommendation
- Safety Assessment Results: The independent Data Safety Monitoring Board (DSMB) has issued its sixth consecutive positive recommendation for the continuation of BriaCell's Phase 3 Bria-ABC study, indicating favorable safety and tolerability of the immunotherapy, which enhances investor confidence in the company's future prospects.
- FDA Fast Track Designation: The study is being conducted under the FDA's Fast Track designation, reflecting a significant unmet medical need in metastatic breast cancer, positioning BriaCell's innovative therapies to potentially fill this market gap and enhance the company's competitiveness in the biotechnology sector.
- Clinical Trial Progress: The positive DSMB recommendation suggests that the combination of Bria-IMT and immune checkpoint inhibitors shows good safety in clinical trials, potentially offering new hope for patients in urgent need of treatment, thereby increasing BriaCell's market recognition.
- Strategic Company Implications: BriaCell's CEO, William V. Williams, noted that this milestone not only recognizes the company's research capabilities but also lays the groundwork for future financing and collaboration opportunities, further driving innovation in cancer treatment.
See More
BriaCell Reports Positive Clinical Data at ASCO 2026
- Survival Rate Data: The latest clinical trial indicates a median overall survival of 16.6 months for Bria-IMT, demonstrating its effectiveness in heavily pre-treated metastatic breast cancer patients, which signifies a crucial clinical advancement in extending patient survival.
- Quality of Life Improvement: The ongoing Phase 3 study shows that patients maintain stable quality of life (QOL) with no significant toxicity, suggesting that the combination of Bria-IMT and immune checkpoint inhibitors can effectively enhance overall health status and has potential for self-administration.
- Biomarker Analysis: The study reveals that 65% of patients experienced stability or a drop in Cancer-Associated Macrophage-Like cells (CAMLs), which significantly correlates with better progression-free survival (PFS), underscoring the importance of biomarkers in predicting treatment efficacy.
- Clinical Data Presentation: BriaCell will showcase six clinical data presentations at the 2026 ASCO Annual Meeting, emphasizing its commitment to innovative cancer treatment options, aiming to provide new hope for patients in need of better therapies.
See More
BriaCell Expands Focus on Women's Health with New Ovarian Cancer Therapy
- New Therapy Development: BriaCell is developing Bria-OVA+, a personalized immunotherapy for ovarian cancer designed to enhance anti-tumor activity through additional immune-stimulating components, reflecting the company's strategic expansion into women's health.
- Market Demand: According to the National Cancer Institute, an estimated 21,010 women in the U.S. will be diagnosed with ovarian cancer by 2026, with approximately 12,450 expected to die from the disease, highlighting the urgent need for new therapies, especially for patients unresponsive to existing treatments.
- Preclinical Data Support: BriaCell recently presented preclinical data for Bria-BRES+ at the AACR conference, demonstrating its ability to activate both adaptive and innate immunity, supporting the potential of the Bria-OTS+ platform and providing a scientific basis for the development of Bria-OVA+.
- Strategic Collaboration: BriaCell has licensed ovarian cancer cell lines from the American Type Culture Collection (ATCC) and has commenced development activities to support the production of Bria-OVA+ for potential clinical use, further solidifying its position in the cancer immunotherapy space.
See More
BriaCell Announces Pricing of 1.45 Million Shares at $3.25 Each
- Funding Size: BriaCell Therapeutics Corp. announced the offering of 1,449,300 common shares at $3.25 each, expecting gross proceeds of approximately $4.7 million, which will be used for working capital and advancing corporate objectives, indicating the company's active engagement in capital markets.
- Offering Arrangement: The offering is being managed solely by ThinkEquity and is expected to close on June 2, 2026, reflecting the company's strategic planning in financing aligned with market demand.
- Compliance Assurance: The company is relying on the exemption set forth in Section 602.1 of the TSX Company Manual, ensuring that the transaction complies with relevant regulations, which enhances investor confidence in the company's compliance.
- Future Outlook: BriaCell intends to use the proceeds to advance its cancer immunotherapy development, demonstrating the company's commitment to long-term growth and innovation in the biotechnology sector, which may attract more investor interest in its future potential.
See More
BriaCell Therapeutics Prices Public Offering at $3.25 per Share
- Public Offering Pricing: BriaCell Therapeutics Corp. has priced its public offering at $3.25 per share for 1.45 million shares, expecting total gross proceeds of approximately $4.7 million, indicating a proactive approach to financing.
- Clear Use of Proceeds: The company intends to utilize the net proceeds for working capital requirements, general corporate purposes, and advancing its business objectives, reflecting a strategic plan for future growth.
- Market Performance Volatility: Over the past year, BCTX's stock has traded between $2.98 and $36.90; despite closing last Friday up 1.68% at $3.64, it fell 12.64% to $3.18 in the overnight market, highlighting the stock's sensitivity to market fluctuations.
- Underwriter's Role: ThinkEquity is acting as the sole placement agent for the offering, underscoring its significant role in the capital markets and potentially influencing investor confidence in the stock.
See More
BriaCell's Immunotherapy Study Receives Positive DSMB Recommendation
- Clinical Trial Progress: BriaCell Therapeutics' Bria-ABC study in metastatic breast cancer has received its sixth consecutive positive recommendation from the independent Data Safety Monitoring Board, indicating no safety concerns and allowing the trial to proceed without modifications.
- FDA Fast Track Designation: Conducted under FDA Fast Track designation, the study underscores the significant unmet medical need in metastatic breast cancer, highlighting the strategic importance of the company's development of novel immunotherapies.
- CEO's Positive Remarks: CEO Dr. William V. Williams described this milestone as 'another step forward,' emphasizing BriaCell's commitment to addressing urgent patient needs and advancing its immunotherapy approach.
- Stock Performance Volatility: BCTX shares have traded between $2.98 and $36.90 over the past year, closing at $3.49, down 6.18% from the previous trading day, reflecting market caution regarding the company's future prospects.
See More
BriaCell's Phase 3 Study Receives Sixth Positive DSMB Recommendation
- Safety Assessment Results: The independent Data Safety Monitoring Board (DSMB) has issued its sixth consecutive positive recommendation for the continuation of BriaCell's Phase 3 Bria-ABC study, indicating favorable safety and tolerability of the immunotherapy, which enhances investor confidence in the company's future prospects.
- FDA Fast Track Designation: The study is being conducted under the FDA's Fast Track designation, reflecting a significant unmet medical need in metastatic breast cancer, positioning BriaCell's innovative therapies to potentially fill this market gap and enhance the company's competitiveness in the biotechnology sector.
- Clinical Trial Progress: The positive DSMB recommendation suggests that the combination of Bria-IMT and immune checkpoint inhibitors shows good safety in clinical trials, potentially offering new hope for patients in urgent need of treatment, thereby increasing BriaCell's market recognition.
- Strategic Company Implications: BriaCell's CEO, William V. Williams, noted that this milestone not only recognizes the company's research capabilities but also lays the groundwork for future financing and collaboration opportunities, further driving innovation in cancer treatment.
See More
BriaCell Reports Positive Clinical Data at ASCO 2026
- Survival Rate Data: The latest clinical trial indicates a median overall survival of 16.6 months for Bria-IMT, demonstrating its effectiveness in heavily pre-treated metastatic breast cancer patients, which signifies a crucial clinical advancement in extending patient survival.
- Quality of Life Improvement: The ongoing Phase 3 study shows that patients maintain stable quality of life (QOL) with no significant toxicity, suggesting that the combination of Bria-IMT and immune checkpoint inhibitors can effectively enhance overall health status and has potential for self-administration.
- Biomarker Analysis: The study reveals that 65% of patients experienced stability or a drop in Cancer-Associated Macrophage-Like cells (CAMLs), which significantly correlates with better progression-free survival (PFS), underscoring the importance of biomarkers in predicting treatment efficacy.
- Clinical Data Presentation: BriaCell will showcase six clinical data presentations at the 2026 ASCO Annual Meeting, emphasizing its commitment to innovative cancer treatment options, aiming to provide new hope for patients in need of better therapies.
See More
BriaCell Expands Focus on Women's Health with New Ovarian Cancer Therapy
- New Therapy Development: BriaCell is developing Bria-OVA+, a personalized immunotherapy for ovarian cancer designed to enhance anti-tumor activity through additional immune-stimulating components, reflecting the company's strategic expansion into women's health.
- Market Demand: According to the National Cancer Institute, an estimated 21,010 women in the U.S. will be diagnosed with ovarian cancer by 2026, with approximately 12,450 expected to die from the disease, highlighting the urgent need for new therapies, especially for patients unresponsive to existing treatments.
- Preclinical Data Support: BriaCell recently presented preclinical data for Bria-BRES+ at the AACR conference, demonstrating its ability to activate both adaptive and innate immunity, supporting the potential of the Bria-OTS+ platform and providing a scientific basis for the development of Bria-OVA+.
- Strategic Collaboration: BriaCell has licensed ovarian cancer cell lines from the American Type Culture Collection (ATCC) and has commenced development activities to support the production of Bria-OVA+ for potential clinical use, further solidifying its position in the cancer immunotherapy space.
See More
